Pharma shares rocket on mega M&A deals

clock

GlaxoSmithKline, the UK's largest pharmaceutical group, and rival AstraZeneca, saw shares jump sharply - with the latter up 10% - as a series of deals in the sector boosted prices.

Glaxo saw shares jump 4.7% when markets opened after it agreed to sell one of its businesses to rival Novartis, in a deal which will see it return billions of pounds to shareholders. But it was rival AstraZeneca which really rocketed, shares jumping 9.7% initially, after reports US rival Pfizer - a much larger company - will bid £60bn for the group. Britain's second-largest drugs maker is expected to do all it can to withstand any approach. Glaxo's gains seem the more sustainable after the group - a favourite holding of many income funds in the UK - today announced it had sold its ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot